N-[[5-[[6-[3-[4-(3-aminopropylamino)butylamino]propylamino]-6-oxohexyl]sulfamoyl]thiophen-2-yl]methyl]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[[5-[[6-[3-[4-(3-aminopropylamino)butylamino]propylamino]-6-oxohexyl]sulfamoyl]thiophen-2-yl]methyl]benzamide
• 化学式: C₂₈H₄₆N₆O₄S₂
• 分子量: 594.8
• InChiKey: SQKFHXFYQIYRAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  40
• 可旋转键数：
  23
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  191
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE
  申请人：McKearn John

  公开号：US20110112199A1

  公开（公告）日：2011-05-12

  Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.
• METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES
  申请人：PATHOLOGICA LLC

  公开号：US20150359761A1

  公开（公告）日：2015-12-17

  Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions.
• US8258186B2
  申请人：——

  公开号：US8258186B2

  公开（公告）日：2012-09-04
• US9616035B2
  申请人：——

  公开号：US9616035B2

  公开（公告）日：2017-04-11
• [EN] PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE<br/>[FR] PRODUIT PHARMACEUTIQUE POUR ADMINISTRATION PAR VOIE ORALE COMPRENANT MGBG ET PROCÉDÉS DE TRAITEMENT DE MALADIE
  申请人：PATHOLOGICA LLC

  公开号：WO2011009039A2

  公开（公告）日：2011-01-20

  Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.